Complexes exhibit structural features and biological activity, suggesting potential therapeutic applications.
Complexes [Cu2(ind)4(EtOH)2] (I), [Cu(ind)2bpy]·1.15MeCN·0.85MeOH (II), and [Cu(ind)(phen)2]+ ·ind–·0.5Hind·1.5H2O (III) were synthesized using slow diffusion of the starting solutions of copper(II) acetate, indole-2-carboxylic acid (Hind), and oligopyridines (2,2'-bipyridine (bpy)/1,10-phenanthroline (phen)). The structures of the complexes were established by single crystal X-ray diffraction and the phase purity was confirmed by powder X-ray diffraction. According to single-crystal X-ray diffraction data, I and II are molecular complexes, while III is an ionic complex comprising the cationic mononuclear [Cu(ind)(phen)2]+ moiety in the independent part of the unit cell and the ind– anion in the outer sphere. The coordination environment of copper(II) cation (C.N.Cu 5) is described by a square pyramid (I, III) or a planar square with C.N.Cu 4 (II). The supramolecular level involves both hydrogen bonds and non-covalent interactions, mainly of the π…π and C–H…π type. The stability of salt solutions of I–III was studied by spectrophotometry in comparison with the free ligands and over a period of 2 days. Complexes I–III were investigated for biological activity: the antimycobacterial activity was evaluated against the non-pathogenic Mycolicibacterium smegmatis strain and the cytotoxicity of III was assessed against the test human ovarian adenocarcinoma cells (SKOV3).
No takes yet. Share an insight, caveat, or question.
Koshenskova et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: